Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 64
- Registration Number
- NCT05478707
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT05407961
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Germany
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT05377333
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸CenExel-HRI, Berlin, New Jersey, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
Basal Plus GLP1-ra on Glycemic Variability in CKD
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Elaine Chow
- Target Recruit Count
- 95
- Registration Number
- NCT05218915
- Locations
- 🇭🇰
Prince of Wales Hospital, Sha Tin, Hong Kong
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT05140694
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 383
- Registration Number
- NCT05048719
- Locations
- 🇸🇰
MEDI-DIA s.r.o., Sabinov, Prešovský Kraj, Slovakia
🇸🇰Funkystuff, Nove Zamky, Slovakia
🇺🇸Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-03-17
- Target Recruit Count
- 120
- Registration Number
- NCT05005741
- Locations
- 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04893148
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, Korea, Republic of
A Study of LY3437943 in Participants With Type 2 Diabetes
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 281
- Registration Number
- NCT04867785
- Locations
- 🇺🇸
Humphreys Diabetes Center, Boise, Idaho, United States
🇺🇸Logan Health Research, Kalispell, Montana, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 245
- Registration Number
- NCT04862234
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Grady Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.